Quark, Nitto Denko collaborate on fibrotic diseases

Quark Pharmaceuticals, a Fremont, CA-based developer of RNAi-based therapeutics, is collaborating with Nitto Denko, a diversified materials manufacturer based in Osaka, Japan, to develop siRNA therapeutics to treat fibrotic diseases. Quark will provide the RNAi technology and Nitto Denko will work on drug delivery. The two companies are aiming for an Investigational New Drug designation by the FDA by early 2012. Release

Suggested Articles

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.

Kindeva, which produces inhalers, transdermal patches and other medical devices, is expanding operations in the St. Paul, Minnesota, area.